Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.

Article  CAS  PubMed  Google Scholar 

Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024;332(7):571–84.

Article  CAS  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

Article  PubMed  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, SURMOUNT-1 Investigators, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.

Article  CAS  PubMed  Google Scholar 

Ansari S, Khoo B, Tan T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(8):447–59.

Article  CAS  PubMed  Google Scholar 

Kusminski CM, Porez-Tilvo D, Muller TD, DiMarchi RD, Tschop MH, Scherer PE. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829–53.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.

Article  CAS  PubMed  Google Scholar 

Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773–86.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–407.

Article  CAS  PubMed  Google Scholar 

Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427–37.

Article  CAS  PubMed  Google Scholar 

Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121.1.

Article  CAS  PubMed  Google Scholar 

Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseid Am Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–73.

Article  PubMed  Google Scholar 

Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514–26.

Article  CAS  PubMed  Google Scholar 

Wegovy label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Accessed 26 Apr 2025. 

Zepbound label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf. Accessed 26 Apr 2025.

Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Front Pharmacol. 2024;13(15):1461398.

Article  Google Scholar 

Lomeli LD, Komali AM, Tsushima Y, et al. The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis. Diabetes Res Clin Pract. 2024;215:111806.

Article  CAS  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25.

Article  CAS  PubMed  Google Scholar 

Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48.

Article  CAS  PubMed  Google Scholar 

Christoffersen BØ, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring). 2022;30(4):841–57.

Article  PubMed  Google Scholar 

Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15(4):310–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang YC, et al. Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities. Proc Natl Acad Sci USA. 2021;118:e2020167118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alley DE, et al. A research agenda: the changing relationship between body weight and health in aging. J Gerontol A Biol Sci Med Sci. 2008;63(11):1257–9.

Article  PubMed  Google Scholar 

Look AHEAD Research Group, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

Article  Google Scholar 

Wing RR, Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the look AHEAD randomized trial. Obesity (Silver Spring). 2021;29(8):1246–58.

Article  PubMed  Google Scholar 

Pownall HJ, Bray GA, Wagenknecht LE, Walkup MP, Heshka S, Hubbard VS, Hill J, Kahn SE, Nathan DM, Schwartz AV, Johnson KC, Look AHEAD Research Group. Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2015;23(3):565–72.

Article  PubMed  Google Scholar 

Johnson KC, Bray GA, Cheskin LJ, Look AHEAD Study Group, et al. The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. J Bone Miner Res. 2017;32(11):2278–87.

Article  PubMed  Google Scholar 

Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl. 4):16–27.

Article  PubMed